Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Terminated 2Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 2Tumor-Agnostic 1

Conditions

Neoplasms 3Neoplasm Metastasis 3Breast Neoplasms 2

Interventions

Cyclophosphamide 909Carboplatin 787pembrolizumab 744Paclitaxel 742Cisplatin 709Bevacizumab 706Gemcitabine 619Docetaxel 579Rituximab 548Radiotherapy 541Dexamethasone 511Nivolumab 488Doxorubicin 444Fluorouracil 392Capecitabine 376Etoposide 358Pemetrexed 337Cytarabine 335Oxaliplatin 333Lenalidomide 328Prednisone 326fludarabine phosphate 316Erlotinib Hydrochloride 314Trastuzumab 300Leucovorin 299fludarabine 296Vincristine 287Filgrastim 284Bortezomib 284Cetuximab 276

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Has results × AZD 8931 × Clear all
NCT00900627 2016-01-20

THYME

AstraZeneca

Phase 1/2 Completed
330 enrolled 20 charts
Breast

Breast Neoplasms, Neoplasm Metastasis, Neoplasms

NCT01579578 2014-09-12

Assess the Efficacy of AZD8931 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Gastric Cancer

AstraZeneca

Phase 2 Terminated
39 enrolled 12 charts
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT01151215 2014-07-25

MINT

AstraZeneca

Phase 2 Terminated
482 enrolled 10 charts
Breast

Breast Neoplasms, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡